{"id":"irinotecan-carboplatin-concurrent-radiation","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Esophagitis"},{"rate":null,"effect":"Pneumonitis"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1351","moleculeType":"Small molecule","molecularWeight":"371.25"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Irinotecan is a topoisomerase I inhibitor that prevents DNA unwinding and repair, while carboplatin is a platinum-based alkylating agent that cross-links DNA strands. When combined with concurrent radiation therapy, these agents work synergistically to induce DNA damage in cancer cells, with radiation providing direct cytotoxic effects. This multimodal approach is designed to improve local and systemic tumor control.","oneSentence":"Irinotecan and carboplatin are chemotherapy agents combined with concurrent radiation therapy to damage cancer cell DNA through multiple mechanisms while radiation directly destroys tumor tissue.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:10.622Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Locally advanced non-small cell lung cancer (NSCLC)"}]},"trialDetails":[{"nctId":"NCT04656041","phase":"PHASE2","title":"Folfox+Irinotecan+Chemort In Esophageal Cancer","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2021-06-29","conditions":"Gastroesophageal Junction Adenocarcinoma, Esophagogastric Cancer","enrollment":40},{"nctId":"NCT00193375","phase":"PHASE2","title":"Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2003-08","conditions":"Lung Cancer","enrollment":60},{"nctId":"NCT00144053","phase":"PHASE3","title":"A Phase Ⅲ Randomized Study of Mitomycin/Vindesine/Cisplatin Versus Irinotecan/Carboplatin Versus Paclitaxel/Carboplatin With Concurrent Thoracic Radiotherapy for Unresectable Stage Ⅲ Non-Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"West Japan Thoracic Oncology Group","startDate":"2001-04","conditions":"Lung Cancer","enrollment":450}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Irinotecan+Carboplatin/concurrent radiation","genericName":"Irinotecan+Carboplatin/concurrent radiation","companyName":"West Japan Thoracic Oncology Group","companyId":"west-japan-thoracic-oncology-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Irinotecan and carboplatin are chemotherapy agents combined with concurrent radiation therapy to damage cancer cell DNA through multiple mechanisms while radiation directly destroys tumor tissue. Used for Locally advanced non-small cell lung cancer (NSCLC).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}